We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In the MORE clinical trial, the use of SIR-Spheres ...
Boston Scientific announced an analysis of 989 patients with hepatocellular carcinoma (HCC) from the PROACTIF prospective ...
A randomized cross-over trial comparing single-agents capecitabine (C) and UFT plus leucovorin (LV) in patients (Pts) with advanced colorectal cancer (CRC): Preliminary data of a patient preference ...
(RTTNews) - Boston Scientific Corp. (BSX) said that late-breaking data demonstrated improved progression-free survival in patients with metastatic colorectal cancer after treatment with boston ...
Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology and embolization solutions, today announced ...
Pivotal DOORwaY90 trial evaluated Sirtex Medical’s Y90 selective internal radiation therapy to treat unresectable HCC. 12-month findings presented at SIR 2026 included a 90% complete response rate and ...
Please provide your email address to receive an email when new articles are posted on . The Asia-Pacific Hepatocellular Carcinoma Trials Group, National Cancer Centre Singapore, Singapore Clinical ...
Validation study of a prognostic classification system in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. Background: Prospective evaluation of the ...
MARLBOROUGH, Mass., March 18, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass ...
ABK Biomedical successfully secured Breakthrough Device Designation from the FDA on December 5, 2023, for its Eye90 microspheres device, which is indicated for the treatment of unresectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results